Clinical study of serum interleukin-6 in children with community-acquired pneumonia

Khattab, Ahmed A.; El-Mekkawy, Muhammad Said; Shehata, A.; Whdan, Nermeen A.

doi:10.1016/j.epag.2018.03.003

Cited by 4 publications

(4 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, Bacci M et al demonstrated that serum levels of IL-6 and TNF-α were correlated with worse outcomes [16]. There are several studies postulating that IL-6 is a marker of severity in CAP both in adults and children [7,19,20,21]. IL-4 has been best studied in the pathogenesis of asthma [22].…”

Section: Discussionmentioning

confidence: 99%

Systemic interleukins levels in community-acquired pneumonia and their association with adverse outcomes

Tripon

Berindan‐Neagoe

Budişan

et al. 2019

Revista Romana De Medicina De Laborator

View full text Add to dashboard Cite

Introduction: Community-acquired pneumonia (CAP) is still one of the major causes of morbidity and mortality worldwide. Pro-inflammatory and anti-inflammatory interleukins have been studied to elucidate the role that inflammation plays in its pathogenesis. The aim of this study is to investigate inflammation in CAP, by analyzing in dynamic, serum levels of six interleukins (IL) and their predictive value regarding adverse outcomes. Materials and methods: Forty adult patients with CAP, admitted in the Teaching Hospital of Infectious Diseases, Cluj-Napoca, Romania from December 2015 to February 2017, were enrolled in this study. Serum levels of pro-inflammatory: IL1β, TNF-α, IL-6, anti-inflammatory: IL-10 and IL-4, along with IL-17A were analyzed in dynamic, on day 1 and day 4.The receiver – operator curves (ROC) were used to analyze the outcome prediction of IL. Results: Serum levels of IL-1β, IL-6, TNF-α and IL-10 have decreased significantly in dynamic, while IL-4 increases. IL-17A has acted like a pro-inflammatory cytokine. We have found a correlation between IL-6 and IL-10 (r=0.429, p=0.000), IL-6 and IL-17A (r=0.295, p=0.008) and IL-10 and IL-17A (r=0.475, p=0.000). Out of 40 patients, 9 had adverse outcomes, consisting in 9 relapses from which 1 died. IL-6 discriminates alone between adverse and favorable outcomes. With multivariate analysis and multiple regression of all combined IL, we have found that there is a predictive model regarding adverse outcomes. Conclusion: IL-10 and IL-17A behave like pro-inflammatory cytokines. IL-6 is a predictive marker for adverse outcomes alone. All IL studied together have an impact on adverse outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Systemic interleukins levels in community-acquired pneumonia and their association with adverse outcomes

Tripon

Berindan‐Neagoe

Budişan

et al. 2019

Revista Romana De Medicina De Laborator

View full text Add to dashboard Cite

show abstract

“…29 Compared to other studies of inflammatory markers in non-COVID-19 pneumonia, CRP and IL-6 were higher in non-COVID-19 pneumonia patients, with a median of 40 (range 12-157) mg/dL and 248.39 (range 92.33-473.9) pg/mL, respectively. 30 A high level of procalcitonin is not specific, as inflammatory cytokines can trigger it as a response to severe bacterial infection. It is also found in severe respiratory viral infection, e.g., severe pneumonia cases caused by human adenovirus.…”

Section: Discussionmentioning

confidence: 99%

Inflammatory and coagulation marker profiles in severe pediatric COVID-19 patients: a systematic review

Fathan

Pudjiadi²,

Putri³

et al. 2022

View full text Add to dashboard Cite

Background Children are susceptible to SARS-CoV-2 infection and often present mild manifestations. However, severe and critical cases have also been reported. The inflammation and coagulation marker profile pattern in these patients along with the white blood cell differential count in critical PICU cases with non-COVID-19 etiology is not entirely clear. Objective To evaluate the inflammation and coagulation profiles in children presenting with severe/critical SARS-CoV-2 infection. Methods A systematic search and review of scientific literature was conducted following the PRISMA guidelines using ProQuest, SCOPUS, EBSCOHost, ScienceDirect, Cochrane, EMBASE, and Pubmed databases. All relevant original studies until March 11, 2021, were included. The risk of bias was appraised using the Modified Newcastle Ottawa Scale and JBI Critical Appraisal Checklist tools. Results We identified 14 studies across 6 countries, including a total sample of 159 severe and critically ill pediatric COVID-19 patients. Most of the subjects showed normal leukocytes, but increased CRP, procalcitonin, ferritin, and IL-6. Studies on coagulation profiles showed normal thrombocytes, PT, aPTT, and inconsistent D-dimer results. Conclusion Inflammation and coagulation parameters in severe/critically ill children with COVID-19 are atypical. Several inflammatory markers were elevated, including CRP, ferritin, procalcitonin, and IL-6. However, the elevated marker values are still lower compared to non-COVID infection patients. Further investigation of the parameters need to be done in serial examination multicenter studies, which include control subjects.

show abstract

“…IL-6 is a protein secreted by 26-kD, a soluble protein produced by T cells that activates B cell differentiation to produce antibodies. 23,24 The pathophysiology of CAP in the early stages is associated with proinflammatory cytokines COVID-19, all of whom had pneumonia. [26][27][28] The treatment group's administration of Omega-3 supplements decreased MDA level significantly.…”

Section: Original Articlementioning

confidence: 99%

“…Several studies have suggested that IL-6 can be used as an independent predictor of CAP mortality. This is based on findings showing a positive correlation between serum IL-6 concentrations and recent mortality in community pneumonia [23][24][25]. Omega-3 plays an important role as an anti-inflammatory resulting from PPAR-γ activation and reduces cytokine production.…”

mentioning

confidence: 99%

The Role of Omega-3 on the IL-6 Levels, Malondialdehyde, and Clinical Improvement in Adults with Community-Acquired Pneumonia

Astarini,

Aphridasari,

Setijadi

2024

J Respirol Indones

View full text Add to dashboard Cite

Background: Acute lung parenchymal infection, known as pneumonia, can be carried on by multiple microorganisms, including bacteria, viruses, fungi, and parasites. Globally, community-acquired pneumonia is a major factor of morbidity, mortality, and health issues. Malondialdehyde (MDA) is a marker of oxidative stress in pneumonia patients, and interleukin 6 (IL-6) is a marker of inflammatory process. Effect of Omega-3 as an immunomodulator, anti-inflammatory, and antioxidant may be implemented as adjunctive therapy in patient with community-acquired pneumonia.Methods: Clinical trial research with a true experimental method and pretest-posttest design. The study involved 30 community-acquired pneumonia patients who were admitted at Moewardi Hospital in Surakarta and Dr. Soehadi Prijonegoro Hospital in Sragen from August to September 2022 by consecutive sampling. The control group (n=15) received standard therapy, and the treatment group (n=15) received standard therapy plus Omega-3 at a dose of 1600 mg/day. IL-6 and MDA levels were measured when the subject was admitted to the hospital and there was clinical improvement.Results: There was a significant difference in reduced IL-6 levels (P=0.001), decreased MDA levels (P=0.001), and the duration of clinical improvement (P=0.042) between the treatment group and the control group. There was a moderate correlation between the decrease in IL-6 (R=0.480) and MDA (R=0.459), while the duration of clinical improvement had a strong correlation (R=0.756) in the treatment group.Conclusion: Supplementation of Omega-3 was effective in reducing IL-6, MDA levels, and the duration of clinical improvement in community-acquired pneumonia patients.

show abstract

Clinical study of serum interleukin-6 in children with community-acquired pneumonia

Cited by 4 publications

References 25 publications

Systemic interleukins levels in community-acquired pneumonia and their association with adverse outcomes

Systemic interleukins levels in community-acquired pneumonia and their association with adverse outcomes

Inflammatory and coagulation marker profiles in severe pediatric COVID-19 patients: a systematic review

The Role of Omega-3 on the IL-6 Levels, Malondialdehyde, and Clinical Improvement in Adults with Community-Acquired Pneumonia

Contact Info

Product

Resources

About